Image de couverture de livre

Response of advanced HCC to pembrolizumab and lenvatinib combination therapy despite monotherapy failure = Ansprechen eines fortgeschrittenen HCC auf Pembrolizumab und Lenvatinib Kombinationstherapie trotz Versagen der Monotherapie

In recent years, immune checkpoint inhibitors (ICIs) were successfully introduced to cancer therapy, and these drugs have already become essential for the treatment of various noncurable tumors. However, monotherapy in advanced hepatocellular carcinoma (aHCC) failed to show statistically significant...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Schulte, Nadine (Auteur) , Li, Moying (Auteur) , Zhan, Tianzuo (Auteur) , Dreikhausen, Lena (Auteur) , Sollors, Janina (Auteur) , Antoni, Christoph Helmer (Auteur) , Diehl, Steffen J. (Auteur) , Schönberg, Stefan (Auteur) , Rahbari, Nuh Nabi (Auteur) , Reißfelder, Christoph (Auteur) , Giordano, Frank Anton (Auteur) , Ebert, Matthias (Auteur) , Teufel, Andreas (Auteur)
Format: Article (Journal)
Langue:anglais
Publié: 12. August 2020
In: Zeitschrift für Gastroenterologie
Year: 2020, Volume: 58, Numéro: 08, Pages: 773-777
ISSN:1439-7803
DOI:10.1055/a-1190-5681
Accès en ligne:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1055/a-1190-5681
Verlag, lizenzpflichtig, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/a-1190-5681
Accéder au texte intégral
Notes sur l'auteur:Nadine Schulte, Moying Li, Tianzuo Zhan, Lena Dreikhausen, Janina Sollors, Christoph Antoni, Steffen Diehl, Stefan O. Schoenberg, Nuh Rahbari, Christoph Reissfelder, Frank A. Giordano, Matthias P. Ebert, Andreas Teufel
Description
Résumé:In recent years, immune checkpoint inhibitors (ICIs) were successfully introduced to cancer therapy, and these drugs have already become essential for the treatment of various noncurable tumors. However, monotherapy in advanced hepatocellular carcinoma (aHCC) failed to show statistically significant improvement.Recently, the combination of atezolizumab and bevacizumab demonstrated efficacy of combining ICI and VEGF inhibition, further substantiating previous data on synergistic mechanisms among respective substance classes.As TKI treatment is currently standard of care for aHCC, and ICIs are approved by the FDA and available in many areas of the world, numerous patients may have been treated with monotherapy of those drugs. However, it remains unclear if failure to monotherapy has an impact on combination therapy. We therefore report a patient well responding to combination therapy despite previous failures to TKI and ICI monotherapy.
Description:Gesehen am 14.08.2026
Description matérielle:Online Resource
ISSN:1439-7803
DOI:10.1055/a-1190-5681

Documents similaires